维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

14篇 您的检索式：作者名="Tayebjee M H"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	Plasma matrix metal- loproteinase-9,tissue inhibitor of metalloproteinase-2,and CD40 ligand levels in patients with stable coronary artery dis- ease显示文摘	Tayebjee M H Lip G Y Tan K T	2005	Am J Cardiol2005，96，3：	1
	2	Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)显示文摘	TAYEBJEE M H NADAR S BLANN A D	2004	AmJ Hypertens2004，17，：	1
	3	Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)显示文摘	Tayebjee M H Nadar S Blann A D	2004	Am J Hypertens2004，17，9：	1
	4	Collateralization and the response to obstruction of epicardial coronary arteries显示文摘	Tayebjee M H Lip G Y MacFadyen R J	2004	QJM2004，97，5：	1
	5	Extracellularmatrix biology: a new frontier in linking the pathology and therapy of hypentension 显示文摘	TAYEBJEE M H MACFADYEN R J LIP G Y	2003	J Hypertens2003，21，12：	1
	6	Plasma matrix metalloproteinase-9,tissue inhibitor of metalloproteinase-2,and CD40 ligand levels in patients with stable coronary artery disease显示文摘	TAYEBJEE M H LIP G Y TAN K T	2005	Am J Cardiol2005，96，：	1
	7	Matrixmetalloproteinase-9 and tissue inhibitor of metal oproteinase-1in hypertension and their relationship to cardiovascular risk andtreatment:a substudy of the Anglo-Scandinavian Cardiac OutcomesTrial (ASCOT)显示文摘	TAYEBJEE M H NADAR S BLANN A D	2009	Am J Hyperterm2009，17，9：	1
	8	Extracellular matrix biology:a new frontier in linking the pathology and therapy of hypertension显示文摘	Tayebjee M H MacFadyen RJ Lip G Y	2003	Hypertension2003，21，12：	1
	9	Target organ damage in hypertension:pathophysiology and implications for drug therapy显示文摘	NADAR S K TAYEBJEE M H MESSERLI F	2006	Curr Pharm Des2006，12，：	1
	10	Can implantable cardiac electronic device infections be defined as early or late based on the cause of infection显示文摘	TAYEBJEE M H JOY E R SANDOE J A	2013	J Med Microbiol2013，62，8：	1
	11	Matrix metalloproteinase-9 and tissue inhibitor ofmetalloproteinase-1 and -2 in type-2 diabetes显示文摘	TAYEBJEE M H LIM M H S MACFADYEN M R J	2004	Diabetes Care2004，27，8：	1
	12	Clinically apparent atherosclerotic disease in diabetes is associated with an increase in platelet microparticle levels显示文摘	Tan K T Tayebjee M H Lim H S	2005	Diab Med2005，22，29：	1
	13	Clinically apparentatherosclerotic disease in diabetes is associated with an increasein platelet microparticle levels显示文摘	Tan K T Tayebjee M H Lim H S	2005	Diabet Med2005，22，12：	1
	14	Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatmeat:a substudy of the anglo-scandinavian cardiac outcomes trial (ASCOT)显示文摘	TAYEBJEE M H NADARS BLANN AD	2004	Am J Hypertens2004，17，9：	1

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费